Research graph
References from Comparative study of safety and efficacy of tofacitinib (2%) and minoxidil (2%) in childhood patchy alopecia areata. Local targets link to admitted publications; unresolved targets remain external evidence.
Alopecia Areata in children: A clinical profile
10.1046/j.1525-1470.2002.00215.x · 2002 · External reference
Epidemiology and genetics of alopecia areata
10.1046/j.1365-2230.2002.01077.x · 2002 · External reference
Alopecia Areata
10.1111/j.1365-4632.2007.03193.x · 2007 · External reference
Alopecia areata: Update on management
10.4103/ijpd.ijpd_80_17 · 2017 · External reference
Systemic tofacitinib in paediatric alopecia areata
10.25259/ijdvl_1109_2023 · 2024 · External reference
Safety of Janus kinase inhibitors in patients with alopecia areata: A systematic review
10.1007/s40261-023-01260-z · 2023 · External reference
Molecular Pathways: Interleukin-15 signaling in health and in cancer
10.1158/1078-0432.ccr-12-3603 · 2014 · External reference
Treatment of alopecia areata with tofacitinib
10.1001/jamadermatol.2017.0001 · 2017 · External reference
Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran
10.1111/jocd.16049 · 2024 · External reference
Treatment of alopecia universalis with topical Janus kinase inhibitors: A double blind, placebo, and active controlled pilot study
10.1111/ijd.14192 · 2018 · External reference
Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning
10.1002/jcph.1360 · 2019 · External reference
Efficacy and safety of topical tofacitinib for the treatment of alopecia areata
10.4103/idoj.idoj_535_23 · 2024 · External reference
Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis
10.1111/jocd.15425 · 2022 · External reference
Treatment of alopecia areata with tofacitinib
10.1001/jamadermatol.2017.0001 · ExternalCitation · doi-reference
Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning
10.1002/jcph.1360 · ExternalCitation · doi-reference
Safety of Janus kinase inhibitors in patients with alopecia areata: A systematic review
10.1007/s40261-023-01260-z · ExternalCitation · doi-reference
Epidemiology and genetics of alopecia areata
10.1046/j.1365-2230.2002.01077.x · ExternalCitation · doi-reference
Alopecia Areata in children: A clinical profile
10.1046/j.1525-1470.2002.00215.x · ExternalCitation · doi-reference
Treatment of alopecia universalis with topical Janus kinase inhibitors: A double blind, placebo, and active controlled pilot study
10.1111/ijd.14192 · ExternalCitation · doi-reference
Alopecia Areata
10.1111/j.1365-4632.2007.03193.x · ExternalCitation · doi-reference
Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis
10.1111/jocd.15425 · ExternalCitation · doi-reference
Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran
10.1111/jocd.16049 · ExternalCitation · doi-reference
Molecular Pathways: Interleukin-15 signaling in health and in cancer
10.1158/1078-0432.ccr-12-3603 · ExternalCitation · doi-reference
Systemic tofacitinib in paediatric alopecia areata
10.25259/ijdvl_1109_2023 · ExternalCitation · doi-reference
Efficacy and safety of topical tofacitinib for the treatment of alopecia areata
10.4103/idoj.idoj_535_23 · ExternalCitation · doi-reference
Alopecia areata: Update on management
10.4103/ijpd.ijpd_80_17 · ExternalCitation · doi-reference
